Analytical Data
-
Gene name
IL-12
- Application
-
Alternative Names
IL-12；NKSF1；Interleukin-12 subunit alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43432
-
Expression Region
23-335aa
-
AA Sequence
MWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSG KTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKN KTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASL SAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYS TSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFV RIQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSS CSKWACVPCRVRS
-
Molecular Weight
36 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant interleukin-12 (IL-12) is a crucial cytokine involved in the regulation of immune responses, particularly in driving Th1 cell differentiation and enhancing cytotoxic T cell activity. Initially discovered for its ability to stimulate T and natural killer (NK) cells, IL-12 has since garnered significant attention in immunotherapy and vaccine development, especially for cancer and infectious diseases. The molecular structure of IL-12, which consists of p35 and p40 subunits, allows for its use in recombinant protein formats that can boost immune responses. Research over the past few decades has demonstrated that IL-12 can potentiate anti-tumor immunity and improve outcomes in various preclinical and clinical settings. However, its clinical application has been limited by potential toxicity and the need for careful dosage management. Recent studies focus on optimizing delivery methods, such as gene therapy and targeted delivery mechanisms, to enhance its therapeutic efficacy while minimizing adverse effects. The continued exploration of recombinant IL-12 is pivotal in harnessing its immunomodulatory properties, aiming to advance therapeutic strategies and pave the way for innovative treatments in oncology and beyond.
